On April 17, 2023, the FDA approved omidubicel-onlv (Omisirge; Gamida Cell), a substantially modified allogeneic cord blood–based cell therapy, to quicken the recovery of neutrophils in the body and reduce the risk for infection in adults and pediatric patients aged ≥12 years with hematologic malignancies who have a planned umbilical cord blood transplant after a myeloablative conditioning regimen, such as radiation or chemotherapy.
The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills.
Molecular/genetic characterization has taken on greater importance in the classification of adult gliomas and in diagnostic and treatment decision-making. “These tumors are now grouped and predicated more on molecular features rather than histopathologic criteria,” said L. Burt Nabors, MD, in a presentation during the 2023 NCCN Annual Conference.
Amgen offers assistance to patients through Amgen Assist 360, Amgen SupportPlus Co-Pay Program, and the Amgen Safety Net Foundation.
AstraZeneca, through its Access 360 and AZ&Me programs, offers a range of patient assistance to help streamline access and reimbursement for select AstraZeneca medicines.
Pfizer offers Pfizer Oncology Together, a patient support program to help patients access their prescribed Pfizer Oncology medications, identify financial assistance options, and connect patients to a dedicated Care Champion.
The Guide to Patient Support Services Index can be sorted by Drug or Company to help you quickly access information about programs offered by pharmaceutical companies and novel cancer drugs approved in 2022.